About Molecular Diagnostics Europe

Cambridge Healthtech Institute’s Seventh International Molecular Diagnostics Europe event will move to a larger venue for 2019 - the Lisbon Marriott Hotel - from 6-9 May. This meeting provides a nexus for diagnostic developers in academia and industry as well as end users in the pharmaceutical and healthcare sector to gain a comprehensive picture of molecular diagnostics in the prenatal, oncology, infectious disease, point-of-care, and liquid biopsy fields, plus new coverage of biomarkers for immunotherapy and companion diagnostics for immuno-oncology. This exciting area has attracted attendance of over 400 delegates to learn what novel technologies, platforms and applications are emerging that will impact future healthcare delivery and pharmaceutical research. Join us this spring at this expanding event at the epicenter of diagnostics.

Plenary Keynote Presentations

Precision Diagnostics in Oncology: Expanding Roles of Liquid Biopsies
Nitzan Rosenfeld, PhD, Senior Group Leader, Cancer Research UK Cambridge Institute, University of Cambridge; CSO, Inivata Ltd., United Kingdom

Legal and Regulatory Developments in Precision Medicine and Diagnostic Devices
Erik Vollebregt, Partner, Axon Lawyers, The Netherlands

2019 Featured Keynote Presentations

Development of a TMB Assay and the Challenges of Harmonizing across Products
Michael Doherty, Senior Vice President, Head of Product Development, Foundation Medicine, United States

New Challenges of CDX Development into the Commercial Marketplace
Omar Perez, PhD, Head of Precision Medicine and Diagnostics, GlaxoSmithKline, United States

Development of an Integrated Platform for Biomarker and Drug Target Discovery Using Proteomics
Anthony Whetton, Director, Stoller Biomarker Discovery Centre, University of Manchester, United Kingdom

Point-of-Care Diagnostics in Europe – How to Improve Selectivity of Antibiotics Use
Anders Larsson, MD, PhD, Professor, Department of Clinical Chemistry and Pharmacology, Uppsala University Hospital, Sweden

Novel Digital PCR and Mutation Enrichment Technologies for the Analysis of Clinically Relevant DNA Alterations in Liquid Biopsies
G. Mike Makrigiorgos, PhD, Professor, Dana Farber Cancer Institute and Harvard Medical School, United States

Liquid Biopsy: The New Diagnostic Concept in Oncology
Klaus Pantel, MD, Professor, Chairman, Institute of Tumor Biology, University Medical Center Hamburg- Eppendorf, Germany